Company AZITRAPAR

Equities

AZTR

US05479L1044

Market Closed - Nyse Other stock markets 04:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
0.0922 ^USD	-30.15%		-35.25%	-89.98%

Jun. 16	Certain Options of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	CI
Jun. 16	Certain Warrants of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	CI

Business Summary

Azitra, Inc. is an early-stage clinical biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. The Companyâs product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.

Number of employees: 10

Sales per Business

USD in Million	2022	Weight	2023	Weight	Delta
Screening and Genetically Engineering Microbes of the Skin 100.0 %	0	100.0 %	1	100.0 %	+141.55%

Sales per region

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	1	100.0 %	+141.55%

Managers

Managers	Title	Age	Since
Francisco Salva CEO	Chief Executive Officer	53	21-05-03
Travis Whitfill FOU	Founder	34	14-01-01
Norman Staskey DFI	Director of Finance/CFO	54	22-09-30

Members of the board

Members of the board	Title	Age	Since
Barbara Ryan BRD	Director/Board Member	64	-
Travis Whitfill FOU	Founder	34	14-01-01
Francisco Salva CEO	Chief Executive Officer	53	21-05-03
John R. Schroer BRD	Director/Board Member	58	-
Andrew McClary BRD	Director/Board Member	38	19-02-28

Shareholders

Name	Equities	%	Valuation
BIOS Capital Management LP 23.09 %	6,652,361	23.09 %	1 M $
Laurence Lytton 5.786 %	1,666,600	5.786 %	311 654 $
BAYER AG 4.539 %	1,307,401	4.539 %	244 484 $
Noam Dunsky 4.146 %	1,194,350	4.146 %	223 343 $
Connecticut Innovations, Inc. 2.104 %	605,907	2.104 %	113 305 $
Altium Capital Management LP 1.712 %	493,153	1.712 %	92 220 $
Sabby Management LLC 1.476 %	425,257	1.476 %	79 523 $
Francisco Salva 1.174 %	338,300	1.174 %	63 262 $
Travis Whitfill 1.161 %	334,500	1.161 %	62 552 $
Warberg Asset Management LLC 1.043 %	300,501	1.043 %	56 194 $